HLA Typing Market

HLA Typing Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Reagent, Software), Application (Chimerism, Antibody Screening), End User (Hospital, Diagnolab, Academia) & Region - Global Forecast to 2028

Report Code: MD 7576 May, 2023, by marketsandmarkets.com

The global HLA typing market in terms of revenue was estimated to be worth $1.4 billion in 2022 and is poised to reach $2.1 billion by 2028, growing at a CAGR of 6.5% from 2022 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growing geriatric population will boost the growth of the market, as elderly individuals are frequently referred for organ transplant procedures due to age or chronic ailment-related organ failure. Diseases such as tuberculosis, end-stage renal disease (ESRD), and liver cirrhosis are more common among seniors and may make it necessary for individuals to undergo organ or tissue transplants.

HLA Typing Market

To know about the assumptions considered for the study, Request for Free Sample Report

Global HLA Typing Market

HLA Typing Market

e- Estimated; p- Projected

HLA typing market: Market Dynamics

Driver: Rising technological advancements in HLA typing

HLA-typing procedures have transitioned from serology-based to genome-based diagnostic techniques due to the advent of PCR-based genome sequencing and its integration with microfluidics, biomedical instrumentation, and robotics. Ongoing technological advancements in HLA typing have resulted in higher sample throughput, increased device sensitivity, early detection of incompatibility, and improved procedural efficacy compared to serological techniques. Such advantages have increased the demand for HLA typing products among key end users such as research laboratories, hospitals, transplant centers, and diagnostic laboratories.

A key development in HLA diagnostics is the introduction of molecular diagnostic techniques such as Sanger sequencing, PCR, HLA-based genotyping, and NGS, which enable the identification of specific alleles and point mutations of HLA genes. Moreover, incorporating nanofabrication and microfluidic technology in PCR procedures is a key factor driving the adoption of PCR and NGS techniques. When combined with bioinformatics tools, NGS approaches provide deep sequencing of complete HLA genes to generate insights on immune disorders in which HLA associations have been implicated. These include rheumatological conditions, coeliac disease, and complex disorders such as type-1 diabetes and systemic lupus erythematosus.

Additionally, several market players have now developed and commercialized PCR and NGS-based HLA typing reagents capable of detecting many genetic changes or identifying specific HLA alleles. For instance, recent developments in line with PCR and NGS-based HLA typing reagents include:

  • In 2021, BD introduced the MX instrument, a fully automated instrument that helps in molecular diagnostics. This instrument is included in the new BD COR system.
  • In 2021, Bio-Rad Laboratories launched the CFX Opus 96 Dx System and CFX Opus 384Dx Systems. These systems are used in quantitative PCR and have uniform thermal performance.
  • In 2022, F. Hoffman LA Roche launched its next-generation PCR. These PCR systems are used for sequencing samples and help reduce human error.

Several prominent players in the life sciences market are involved in developing and commercializing innovative HLA typing reagents, software, and instruments. These players include Abbott Laboratories, Inc., Bio-Rad Laboratories, Inc., and F. Hoffmann-La Roche Ltd. With the growing focus of market players on launching technologically advanced PCR, NGS, and Sanger sequencing-based diagnostics, the market is expected to witness significant growth.

Opportunity: Rising adoption of cross-matching and chimerism testing procedures

Cross-matching is an important procedure during donor-recipient screening that can eliminate the clinical risk of immune rejection or pathogenic or other disorders in recipients. Surgeons usually perform transplantation procedures after ascertaining the results of cross-matching with the help of HLA typing during the pre-transplantation period.

Chimerism testing permits the detection and timely treatment of graft rejection or future relapse. Chimerism testing is also witnessing increasing demand as it analyzes genomic polymorphisms (STR loci) in prospective donors. Chimerism testing uses PCR-based STR/CE systems, including HLA typing. These procedures offer clinical advantages in terms of higher accuracy in patients with graft failure and leukopenia.

Challenge: Limited number of organ donations and long waiting lists for transplantations

There is a significant gap between the number of organs donated annually and the number of organ donations required. The number of patients waiting for organ transplants continuously increases across major countries worldwide. For example, there was a 37.2% increase in waiting list patients for organ transplants in the US, which increased from 83,731 to 113,000 from 2003–July 2019 (Source: US Department of Health and Human Services, 2018). As of December 2021, the European Union had 150,000 patients on the organ donation waiting list (Source: Council of Europe, 2021).

The limited number of organs donated annually worldwide is primarily due to strict government laws that limit medical reimbursements for living organ donors and a lack of public awareness about organ donation, especially in developing countries. This is further aggravated by the lower proportion of organ donations through deceased donors, mainly due to socio-ethical concerns.

Restraint: High cost of HLA typing products

HLA typing is conducted through specialized molecular diagnostic platforms with advanced technologies such as nanofabrication, microfluidics, device automation, and robotics. These advanced technologies are integrated with conventional PCR/NGS instruments to achieve the desired process outcomes, reduce cycle times, and increase sample throughput.

However, such innovative instruments require significant capital investments and extensive scientific validation for market commercialization. Most NGS or PCR-based assay manufacturers offer their instruments at premium prices. Thus, healthcare providers offer NGS and PCR-based diagnostic assays at high procedural costs. For instance, Illumina’s Trusight HLA V2, an amplicon based NGS HLA typing kit, costs around USD 5,000 for 11 HLA genes of 24 samples; this amounts to USD 208 per sample. This is further loaded with additional sequencing costs of around USD 5 (0.3 M, pair-end 100 bp on Illumina X10 platform) per sample.

HLA Typing Market Ecosystem

By technology, the molecular assay technologies segment accounted for the largest share of the HLA typing market during the forecast period.

The molecular assay technologies segment accounted for the largest share of 86.5% in 2022. This segment is projected to reach USD 1,913.3 million by 2028 from USD 1,360 million in 2023, at a CAGR of 6.9% during the forecast period.

By Product & Services, the Reagents & Consumables segment holds the largest share of the HLA typing market.

The reagents & consumables segment accounted for the largest share of 71.8% of the market in 2022. This segment is also projected to register the highest CAGR during the forecast period.

By Application, the diagnostic applications segment accounted for the largest share of the HLA typing market during the forecast period.

The diagnostic applications segment accounted for the largest share of 95.6% of the global market in 2022.

By End User, the commercial service providers segment of HLA typing market is expected to grow at the fastest rate during the forecast period.

The commercial service providers segment accounted for the largest share of 60.2% of the market in 2022. This segment is also projected to register the highest CAGR of 7.0%, reaching USD 1,295.7 million in 2028 from an estimated value of USD 917.1 million in 2023.

North America is expected to be the largest region in the global HLA typing market during the forecast period.

North America accounted for the largest share of 45.0% of the global market.

The large share of the North American market is attributed to the high adoption of advanced diagnostic technologies, the increasing prevalence of target diseases, and technological advancements.

Europe accounted for the second-largest share of 29.5% of the global market in 2021.

The Asia Pacific market is estimated to grow at the highest CAGR of 7.5% during the forecast period.

HLA Typing Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Prominent players in the market include Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (US), and bioMérieux S.A. (France). Other players in the market are Immucor, Inc. (US), among others.

HLA Typing Market Report Scope

Report Metric 

Details 

Market Revenue in 2022

$1.4 billion

Projected Revenue by 2028

$2.1 billion

Revenue Rate

Poised to grow at a CAGR of 6.5%

Market Driver

Rising technological advancements in HLA typing

Market Opportunity

Rising adoption of cross-matching and chimerism testing procedures

This study categorizes the global HLA typing market to forecast revenue and analyze trends in each of the following submarkets:

By Technology

  • Molecular Assay Technologies
    • PCR-based Molecular Assays
      • Sequence-specific Primer-PCR
      • Sequence-specific Oligonucleotide-PCR
      • Other PCR-based Molecular Assays
    • Sequencing-based Molecular Assays
      • Sanger Sequencing
      • Next-generation Sequencing
      • Pyrosequencing
  • Non-molecular Assay Technologies

By Product & Service

  • Reagents & Consumables
  • Instruments
  • Software & Services

By Application

  • Diagnostic Applications
  • Research Applications
  • Donor-recipient cross-matching
  • Infectious disease testing
  • Cancer diagnosis & prevention
  • Transfusion therapy
  • Other diagnostic applications

By End User

  • Commercial service providers
  • Hospitals & surgical centers
  • Research laboratories & academic institutes

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

Recent Developments

  • In March 2023, BioRad received The company received AOAC International and AFNOR approval for its iQ-Check kits, which are used with the CFX Opus Deepwell Real-time PCR System
  • In August 2022 Roche developed a new digital Light cycler system that helps determine a patient’s cancer.
  • In May 2022, CareDx received CE marking for its AlloSeq HCT chimerism testing kit and AlloSeq HCT software. These AlloSeq are used in patients who have received Hematopoietic cell transplantation.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 27)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 GEOGRAPHIES COVERED
           1.3.3 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 STAKEHOLDERS 
    1.6 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 31)
    2.1 RESEARCH DATA 
          FIGURE 1 HLA TYPING MARKET: RESEARCH METHODOLOGY
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 2 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Insights from primary experts
                    2.1.2.3 Breakdown of primary interviews
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
          FIGURE 5 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 6 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ESTIMATION 
    2.5 RESEARCH ASSUMPTIONS 
    2.6 LIMITATIONS 
           2.6.1 METHODOLOGY-RELATED LIMITATIONS
    2.7 RISK ASSESSMENT 
          TABLE 1 LIMITATIONS AND ASSOCIATED RISKS
    2.8 MARKET: RECESSION IMPACT 
 
3 EXECUTIVE SUMMARY (Page No. - 43)
    FIGURE 7 HLA TYPING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    FIGURE 8 MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    FIGURE 9 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 10 MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 ASIA PACIFIC REGION TO DOMINATE MARKET DURING FORECAST PERIOD
 
4 PREMIUM INSIGHTS (Page No. - 47)
    4.1 HLA TYPING MARKET OVERVIEW 
          FIGURE 12 INCREASING NUMBER OF ORGAN TRANSPLANTATIONS AND RISING ADOPTION OF DONOR RECIPIENT CROSS-MATCHING TO DRIVE MARKET
    4.2 MARKET, BY DIAGNOSTIC APPLICATIONS, 2023 VS. 2028 (USD MILLION) 
          FIGURE 13 DONOR RECIPIENT CROSS-MATCHING SEGMENT TO DOMINATE DIAGNOSTIC APPLICATIONS DURING FORECAST PERIOD
    4.3 MARKET: ASIA PACIFIC, BY PRODUCT & SERVICE (2022) 
          FIGURE 14 REAGENTS & CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN CHINA
    4.4 MARKET: GEOGRAPHICAL SNAPSHOT 
          FIGURE 15 CHINA TO DOMINATE MARKET DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 51)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 16 HLA TYPING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising number of organ transplantation procedures
                    5.2.1.2 Rising technological advancements in HLA typing
                    5.2.1.3 Increasing funding investments for research activities
                                TABLE 2 PUBLIC-PRIVATE INVESTMENTS AND RESEARCH GRANTS FOR HLA TYPING PRODUCTS, 2019–2022
                    5.2.1.4 Growing prevalence of infectious diseases
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of HLA typing products
                                TABLE 3 COST OF ASSAYS FOR KEY NGS AND PCR-BASED GENOMIC TESTS IN EUROPE (AS OF 2020)
                    5.2.2.2 Limited reimbursements for target procedures
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Rising adoption of cross-matching and chimerism testing procedures
                    5.2.3.2 Growing awareness of organ donations
           5.2.4 CHALLENGES
                    5.2.4.1 Limited number of organ donations and long waiting lists for transplantations
                    5.2.4.2 Shortage of skilled professionals
    5.3 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 4 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.3.1 THREAT OF NEW ENTRANTS
           5.3.2 THREAT OF SUBSTITUTES
           5.3.3 BARGAINING POWER OF SUPPLIERS
           5.3.4 BARGAINING POWER OF BUYERS
           5.3.5 INTENSITY OF COMPETITIVE RIVALRY
    5.4 REGULATORY ANALYSIS 
           5.4.1 NORTH AMERICA
                    5.4.1.1 US
                                TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION
                                TABLE 6 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
                    5.4.1.2 Canada
                                TABLE 7 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
           5.4.2 EUROPE
           5.4.3 ASIA PACIFIC
                    5.4.3.1 Japan
                                TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA)
                    5.4.3.2 China
                                TABLE 9 CHINA: CLASSIFICATION OF MEDICAL DEVICES
                    5.4.3.3 India
    5.5 MARKET: ECOSYSTEM MAPPING 
          FIGURE 17 ECOSYSTEM COVERAGE
    5.6 VALUE CHAIN ANALYSIS 
           5.6.1 RESEARCH AND DEVELOPMENT
           5.6.2 MANUFACTURING AND ASSEMBLY
           5.6.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
                    FIGURE 18 VALUE CHAIN ANALYSIS
    5.7 SUPPLY CHAIN ANALYSIS 
           5.7.1 PROMINENT COMPANIES
           5.7.2 SMALL AND MEDIUM-SIZED ENTERPRISES
                    FIGURE 19 SUPPLY CHAIN ANALYSIS
    5.8 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
                    FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
                    TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF HLA TYPING PRODUCTS
           5.8.2 BUYING CRITERIA
                    FIGURE 21 KEY BUYING CRITERIA FOR HLA TYPING PRODUCTS
                    TABLE 11 KEY BUYING CRITERIA FOR HLA TYPING PRODUCTS
    5.9 PATENT ANALYSIS 
          FIGURE 22 TOP 10 PATENT APPLICANTS FOR HLA TYPING
    5.10 IMPACT OF RECESSION ON MARKET 
 
6 HLA TYPING MARKET, BY PRODUCT & SERVICE (Page No. - 69)
    6.1 INTRODUCTION 
          TABLE 12 MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
    6.2 REAGENTS & CONSUMABLES 
           6.2.1 WIDE APPLICATIONS OF MOLECULAR ASSAY TECHNIQUES TO DRIVE MARKET
                    TABLE 13 MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2021–2028 (USD MILLION)
    6.3 INSTRUMENTS 
           6.3.1 GROWING ADOPTION OF PCR AND NGS INSTRUMENTS AMONG CROS AND HOSPITALS TO FUEL MARKET
                    TABLE 14 MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION)
    6.4 SOFTWARE & SERVICES 
           6.4.1 RISING DEMAND FOR AUTOMATION AND DIGITALIZATION IN LAB PROCEDURES TO DRIVE MARKET
                    TABLE 15 MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021–2028 (USD MILLION)
 
7 HLA TYPING MARKET, BY TECHNOLOGY (Page No. - 73)
    7.1 INTRODUCTION 
          TABLE 16 MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
    7.2 MOLECULAR ASSAY TECHNOLOGIES 
          TABLE 17 MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 18 MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
          TABLE 19 MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 20 MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 2021–2028 (USD MILLION)
          TABLE 21 MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION)
           7.2.1 PCR-BASED MOLECULAR ASSAYS
                    TABLE 22 MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 23 MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 2021–2028(USD MILLION)
                    TABLE 24 MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY APPLICATION, 2021–2028 (USD MILLION)
                    TABLE 25 MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY END USER, 2021–2028 (USD MILLION)
                    TABLE 26 MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY REGION, 2021–2028 (USD MILLION)
                    7.2.1.1 Sequence-specific Primer-PCR
                               7.2.1.1.1 Expanding distribution channels of key PCR manufacturers to support market growth
                                              TABLE 27 MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2021–2028 (USD MILLION)
                    7.2.1.2 Sequence-specific Oligonucleotide-PCR
                               7.2.1.2.1 Rising need for SSO-PCR-based molecular assays in disease diagnosis to drive market
                                              TABLE 28 MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2021–2028 (USD MILLION)
                    7.2.1.3 Real-time PCR
                               7.2.1.3.1 Increasing preference for genome-based molecular diagnostics to support market growth
                                              TABLE 29 MARKET FOR REAL-TIME PCR, BY REGION, 2021–2028 (USD MILLION)
                    7.2.1.4 Other PCR-based molecular assays
                                 TABLE 30 MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY REGION, 2021–2028 (USD MILLION)
           7.2.2 SEQUENCING-BASED MOLECULAR ASSAYS
                    TABLE 31 MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 32 MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                    TABLE 33 MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY APPLICATION, 2021–2028 (USD MILLION)
                    TABLE 34 MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY END USER, 2021–2028 (USD MILLION)
                    TABLE 35 MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2021–2028 (USD MILLION)
                    7.2.2.1 Sanger sequencing
                               7.2.2.1.1 Rising end-user preference for low-cost and efficient DNA sequencing technology to drive segment growth
                                              TABLE 36 MARKET FOR SANGER SEQUENCING, BY REGION, 2021–2028 (USD MILLION)
                    7.2.2.2 Next-generation Sequencing
                               7.2.2.2.1 High scalability, low turnaround time, and high throughput capabilities to drive segment growth
                                              TABLE 37 MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2021–2028 (USD MILLION)
                    7.2.2.3 Other sequencing-based molecular assays
                                TABLE 38 MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2021–2028 (USD MILLION)
    7.3 NON-MOLECULAR ASSAY TECHNOLOGIES 
           7.3.1 HIGH PREFERENCE OF MOLECULAR-BASED TECHNIQUES TO RESTRAIN MARKET
                    TABLE 39 MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                    TABLE 40 MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 2021–2028 (USD MILLION)
                    TABLE 41 MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 2021–2028 (USD MILLION)
                    TABLE 42 MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION)
 
8 HLA TYPING MARKET, BY APPLICATION (Page No. - 89)
    8.1 INTRODUCTION 
          TABLE 43 MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
    8.2 DIAGNOSTIC APPLICATIONS 
          TABLE 44 MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 45 MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
           8.2.1 DONOR-RECIPIENT CROSS-MATCHING
                    8.2.1.1 Rising need for histocompatibility cross-matching in organ transplantation to drive market
                                TABLE 46 MARKET FOR DONOR-RECIPIENT CROSS-MATCHING, BY REGION, 2021–2028 (USD MILLION)
           8.2.2 INFECTIOUS DISEASE TESTING
                    8.2.2.1 Rising burden of infectious diseases to drive adoption of HLA antigen screening
                                TABLE 47 MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2021–2028 (USD MILLION)
           8.2.3 CANCER DIAGNOSIS & PREVENTION
                    8.2.3.1 Wide availability of advanced NGS techniques to drive adoption of HLA typing in cancer diagnostics
                                TABLE 48 MARKET FOR CANCER DIAGNOSIS & PREVENTION, BY REGION, 2021–2028 (USD MILLION)
           8.2.4 TRANSFUSION THERAPY
                    8.2.4.1 Minimal risk of fatal disorders during blood transfusions to drive adoption of HLA typing
                                TABLE 49 MARKET FOR TRANSFUSION THERAPY, BY REGION, 2021–2028(USD MILLION)
           8.2.5 OTHER DIAGNOSTIC APPLICATIONS
                    TABLE 50 MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
    8.3 RESEARCH APPLICATIONS 
           8.3.1 RISING FUNDING FOR RESEARCH AND EXPANDING APPLICATIONS OF HLA TYPING TO DRIVE MARKET
                    TABLE 51 MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
 
9 HLA TYPING MARKET, BY END USER (Page No. - 97)
    9.1 INTRODUCTION 
          TABLE 52 MARKET, BY END USER, 2021–2028 (USD MILLION)
    9.2 COMMERCIAL SERVICE PROVIDERS 
           9.2.1 RISING ESTABLISHMENT OF REFERENCE LABORATORIES IN EMERGING ECONOMIES TO DRIVE MARKET
                    TABLE 53 MARKET FOR COMMERCIAL SERVICE PROVIDERS, BY REGION, 2021–2028 (USD MILLION)
    9.3 HOSPITALS AND TRANSPLANT CENTERS 
           9.3.1 INCREASING DEMAND FOR ADVANCED EQUIPMENT IN HOSPITALS TO DRIVE MARKET
                    TABLE 54 MARKET FOR HOSPITALS AND TRANSPLANT CENTERS, BY REGION, 2021–2028 (USD MILLION)
    9.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES 
           9.4.1 RISING GOVERNMENT SUPPORT FOR CANCER RESEARCH TO BOOST MARKET GROWTH
                    TABLE 55 MARKET FOR RESEARCH LABORATORIES AND ACADEMIC INSTITUTES, BY REGION, 2021–2028(USD MILLION)
 
10 HLA TYPING MARKET, BY REGION (Page No. - 101)
     10.1 INTRODUCTION 
             TABLE 56 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             FIGURE 23 MARKET: NORTH AMERICA SNAPSHOT
             TABLE 57 NORTH AMERICA: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 58 NORTH AMERICA: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 59 NORTH AMERICA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 60 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 61 NORTH AMERICA: MARKET, BY APPLICATION 2021–2028 (USD MILLION)
             TABLE 62 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.1 US
                        10.2.1.1 High volume of stem cell and bone marrow transplantation procedures to drive market
                                      TABLE 63 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN US, 2021–2022
                                      TABLE 64 NEW CANCER CASES IN US, 2021
                                      TABLE 65 US: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 66 US: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 67 US: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 High prevalence of cancer to drive adoption of HLA typing
                                      TABLE 68 CANADA: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 69 CANADA: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 70 CANADA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
     10.3 EUROPE 
              TABLE 71 EUROPE: HLA TYPING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
              TABLE 72 EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
              TABLE 73 EUROPE: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
              TABLE 74 EUROPE: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
              TABLE 75 EUROPE: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
              TABLE 76 EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
              TABLE 77 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Strong presence of established manufacturers for HLA typing products to drive market
                                      TABLE 78 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN GERMANY, BY TYPE, 2020–2021
                                      TABLE 79 TARGET DISEASE INCIDENCE IN GERMANY (2021)
                                      TABLE 80 NEW CANCER CASES IN GERMANY, BY ORGAN (2021)
                                      TABLE 81 GERMANY: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 82 GERMANY: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 83 GERMANY: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
             10.3.2 UK
                        10.3.2.1 Rising prevalence of autoimmune diseases to drive market
                                      TABLE 84 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN UK, 2021–2022
                                      TABLE 85 TARGET DaISEASE INCIDENCE IN UK, 2021
                                      TABLE 86 NEW CANCER CASES IN UK, 2021
                                      TABLE 87 UK: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 88 UK: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 89 UK: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Rising organ rejection rate to drive market
                                      TABLE 90 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN FRANCE, 2021–2022
                                      TABLE 91 NEW CANCER CASES IN FRANCE, 2021
                                      TABLE 92 FRANCE: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 93 FRANCE: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, 2021–2028 (USD MILLION)
                                      TABLE 94 FRANCE: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES ASSAYS, BY TYPE, 2021–2028 (USD MILLION)
             10.3.4 ITALY
                        10.3.4.1 Increasing acceptance of molecular assay technologies for personalized medicine to drive market
                                      TABLE 95 ITALY: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 96 ITALY: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 97 ITALY: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 Rising number of solid-organ transplantation procedures to support market growth
                                      TABLE 98 SPAIN: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 99 SPAIN: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 100 SPAIN: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
             10.3.6 REST OF EUROPE
                        TABLE 101 REST OF EUROPE: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 102 REST OF EUROPE: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 103 REST OF EUROPE: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES ASSAYS, BY TYPE, 2021–2028 (USD MILLION)
     10.4 ASIA PACIFIC 
             FIGURE 24 HLA TYPING MARKET: ASIA PACIFIC SNAPSHOT
             TABLE 104 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 105 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 106 ASIA PACIFIC: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 107 ASIA PACIFIC: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 108 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 109 ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 110 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.1 CHINA
                        10.4.1.1 Rising adoption of HLA typing for donor-recipient screening to drive market
                                      TABLE 111 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN CHINA, 2021–2022
                                      TABLE 112 NEW CANCER CASES IN CHINA, 2021
                                      TABLE 113 CHINA: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 114 CHINA: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 115 CHINA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
             10.4.2 INDIA
                        10.4.2.1 Government initiatives to provide free availability of HLA typing products to drive market
                                      TABLE 116 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN INDIA, 2021–2022
                                      TABLE 117 NEW CANCER CASES IN INDIA, 2021
                                      TABLE 118 INDIA: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 119 INDIA: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 120 INDIA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
             10.4.3 JAPAN
                        10.4.3.1 Increasing budgetary allocations for healthcare to support market growth
                                      TABLE 121 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN JAPAN, 2021–2022
                                      TABLE 122 NEW CANCER CASES IN JAPAN, 2021
                                      TABLE 123 JAPAN: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 124 JAPAN: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 125 JAPAN: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
             10.4.4 AUSTRALIA
                        10.4.4.1 Rising prevalence of coeliac disease to drive adoption of HLA typing
                                      TABLE 126 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN AUSTRALIA, 2021–2022
                                      TABLE 127 NEW CANCER CASES IN AUSTRALIA, 2021
                                      TABLE 128 AUSTRALIA: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 129 AUSTRALIA: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 130 AUSTRALIA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
             10.4.5 SOUTH KOREA
                        10.4.5.1 Rising adoption of next-generation exome sequencing to drive market
                                      TABLE 131 SOUTH KOREA: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 132 SOUTH KOREA: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 133 SOUTH KOREA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES ASSAYS, BY TYPE, 2021–2028 (USD MILLION)
             10.4.6 REST OF ASIA PACIFIC
                        TABLE 134 REST OF ASIA PACIFIC: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 135 REST OF ASIA PACIFIC: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 136 REST OF ASIA PACIFIC: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES ASSAYS, BY TYPE, 2021–2028 (USD MILLION)
     10.5 LATIN AMERICA 
              TABLE 137 LATIN AMERICA: HLA TYPING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
              TABLE 138 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
              TABLE 139 LATIN AMERICA: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
              TABLE 140 LATIN AMERICA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
              TABLE 141 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
              TABLE 142 LATIN AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
              TABLE 143 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.1 BRAZIL
                        10.5.1.1 Supportive government regulations for adoption of advanced technologies to drive market
                                      TABLE 144 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN BRAZIL, 2021–2022
                                      TABLE 145 NEW CANCER CASES IN BRAZIL, 2021
                                      TABLE 146 BRAZIL: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 147 BRAZIL: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 148 BRAZIL: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
             10.5.2 MEXICO
                        10.5.2.1 Improving accessibility and affordability of healthcare services to support market growth
                                      TABLE 149 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN MEXICO, 2021–2022
                                      TABLE 150 NEW CANCER CASES IN MEXICO, 2021
                                      TABLE 151 MEXICO: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 152 MEXICO: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 153 MEXICO: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
             10.5.3 REST OF LATIN AMERICA
                        TABLE 154 REST OF LATIN AMERICA: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 155 REST OF LATIN AMERICA: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 156 REST OF LATIN AMERICA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
     10.6 MIDDLE EAST AND AFRICA 
             10.6.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO FUEL MARKET
                        TABLE 157 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 158 MIDDLE EAST & AFRICA: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 159 MIDDLE EAST & AFRICA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES ASSAYS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 160 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 161 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 162 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 146)
     11.1 INTRODUCTION 
     11.2 STRATEGIES ADOPTED BY KEY PLAYERS 
              TABLE 163 HLA TYPING MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
     11.3 MARKET SHARE ANALYSIS 
              FIGURE 25 MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
     11.4 COMPETITIVE LEADERSHIP MAPPING 
             11.4.1 STARS
             11.4.2 EMERGING LEADERS
             11.4.3 PERVASIVE PLAYERS
             11.4.4 PARTICIPANTS
                        FIGURE 26 MARKET: COMPETITIVE LEADERSHIP MAPPING (2021)
     11.5 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2021) 
             11.5.1 PROGRESSIVE COMPANIES
             11.5.2 RESPONSIVE COMPANIES
             11.5.3 DYNAMIC COMPANIES
             11.5.4 STARTING BLOCKS
                        FIGURE 27 MARKET: COMPANY EVALUATION MATRIX FOR SMES/STARTUPS, 2021
     11.6 COMPETITIVE BENCHMARKING 
              TABLE 164 MARKET: PRODUCT ANALYSIS FOR KEY PLAYERS
              TABLE 165 MARKET: APPLICATION FOOTPRINT ANALYSIS FOR KEY PLAYERS
              TABLE 166 MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
     11.7 COMPETITIVE SCENARIO 
             11.7.1 PRODUCT LAUNCHES
                        TABLE 167 MARKET: PRODUCT LAUNCHES (2019–2022)
             11.7.2 DEALS
                        TABLE 168 MARKET: DEALS (2019–2022)
 
12 COMPANY PROFILES (Page No. - 158)
     12.1 KEY PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             12.1.1 BD
                        TABLE 169 BD: COMPANY OVERVIEW (2021)
                        FIGURE 28 BD: COMPANY SNAPSHOT (2021)
             12.1.2 BIO-RAD LABORATORIES, INC.
                        TABLE 170 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW (2021)
                        FIGURE 29 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
             12.1.3 F. HOFFMAN-LA ROCHE LTD.
                        TABLE 171 F. HOFFMAN-LA ROCHE LTD: COMPANY OVERVIEW (2021)
                        FIGURE 30 F. HOFFMAN-LA ROCHE LTD: COMPANY SNAPSHOT (2021)
             12.1.4 CAREDX, INC.
                        TABLE 172 CAREDX, INC.: COMPANY OVERVIEW (2021)
                        FIGURE 31 CAREDX, INC.: COMPANY SNAPSHOT (2021)
             12.1.5 HOLOGIC, INC.
                        TABLE 173 HOLOGIC, INC.: COMPANY OVERVIEW (2021)
                        FIGURE 32 HOLOGIC, INC.: COMPANY SNAPSHOT (2021)
             12.1.6 ILLUMINA, INC.
                        TABLE 174 ILLUMINA, INC.: COMPANY OVERVIEW (2021)
                        FIGURE 33 ILLUMINA, INC.: COMPANY SNAPSHOT (2021)
             12.1.7 IMMUCOR, INC.
                        TABLE 175 IMMUCOR, INC.: COMPANY OVERVIEW (2021)
                        FIGURE 34 IMMUCOR, INC.: COMPANY SNAPSHOT (2021)
             12.1.8 OMIXON INC.
                        TABLE 176 OMIXON INC.: COMPANY OVERVIEW (2021)
             12.1.9 QIAGEN N.V.
                        TABLE 177 QIAGEN N.V.: COMPANY OVERVIEW (2021)
                        FIGURE 35 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
             12.1.10 TAKARA BIO INC.
                        TABLE 178 TAKARA BIO INC.: COMPANY OVERVIEW (2021)
                        FIGURE 36 TAKARA BIO, INC: COMPANY SNAPSHOT (2021)
             12.1.11 THERMO FISHER SCIENTIFIC
                        TABLE 179 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW (2021)
                        FIGURE 37 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021)
             12.1.12 BIOFORTUNA LIMITED
             12.1.13 GENDX
                        TABLE 180 GENDX: COMPANY OVERVIEW (2021)
     12.2 OTHER PLAYERS 
             12.2.1 FUJIREBIO
             12.2.2 CREATIVE BIOLABS
             12.2.3 ALPHA BIOTECH LIMITED
             12.2.4 BAG DIAGNOSTICS GMBH
             12.2.5 HANSA BIOPHARMA AB
             12.2.6 HISTOGENETICS LLC
             12.2.7 PACBIO
             12.2.8 TBG DIAGNOSTICS LIMITED
             12.2.9 INNO-TRAIN DIAGNOSTIK GMBH
             12.2.10 KRISHGEN BIOSYSTEMS
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 214)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the microcatheter market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the medical aesthetic market. The primary sources from the demand side include medical OEMs, Oncologists, CDMOs and service providers, among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents is provided below:

HLA Typing Market Size, and Share

*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note: Companies are classified into tiers based on their total revenue. As of 2021, Tier 1 = >USD 1,000 million, Tier 2 = USD 500–1,000 million, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Estimation Methodology

In this report, the HLA Typing Market size was arrived at by using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the HLA Typing business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and key marketing executives.

To calculate the global market value, segmental revenues were calculated based on the revenue mapping of major solution/service providers. This process involved the following steps:

  • Generating a list of major global players operating in the Market
  • Mapping annual revenues generated by major global players from the product segment (or nearest reported business unit/product category)
  • Revenue mapping of major players to cover major share of the global market share, as of 2021.
  • Extrapolating the global value of the Market

HLA Typing Market Size, and Share

Approaches

Bottom-up Approach

HLA Typing Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

  • For estimating the size of the HLA Typing Market, the country-level market revenues were obtained from secondary sources and through extensive primary interviews.
  • Country-level markets for the US and Canada were added to arrive at the market size for North America. Similarly, country-level markets for other countries were added to arrive at the market size of Europe and Asia Pacific.
  • The total market derived through the bottom-up approach was again validated through secondary sources and primary sources.

Top-down approach

HLA Typing Market Size, and Share

  • The overall market size derived from the bottom-up approach was used in the top-down procedure to estimate the size of the subsegment.
  • Percentage splits were applied to the total market size (splits were obtained from secondary and primary research) to obtain the market size for each subsegment.
  • The top-down approach was used to reach the regional and country-level market size for these subsegments.

Data Triangulation

After arriving at the overall market size from the market size estimation process explained above, the HLA Typing Market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the market was validated using both top-down and bottom-up approaches.

Market definition

HLA Typing procedures are used to determine donor-recipient compatibility to avoid immune rejection in a recipient. These procedures are adopted for donor-recipient cross-matching, subject profiling, genotyping, and other related diagnostic tests. Advanced genomic techniques (such as PCR and NGS) are increasingly being used during HLA Typing procedures, apart from serological and other conventional techniques for immune-compatibility testing.

Key stakeholders

  • HLA Typing product manufacturing companies.
  • Healthcare service providers (Including hospitals, transplant centers and blood transfusion centers)
  • Blood, tissue, and stem cell banks
  • Government Organizations
  • Independent association and regulatory authorities
  • R&D companies
  • Independent reference laboratories
  • Diagnostic Laboratories
  • Clinical Research organizations

Objectives of the Study

  • To define, describe, and forecast the HLA Typing Market based on Technology, Product & Service, Application, End User & Region.
  • To provide detailed information regarding the major factors influencing the growth potential of the Market (drivers, restraints, opportunities, challenges, and trends)
  • To analyze the micro markets with respect to individual growth trends, prospects, and contributions to the Market
  • To analyze key growth opportunities in the Market for key stakeholders and provide details of the competitive landscape for market leaders.
  • To forecast the size of market segments and/or subsegments with respect to five major regions, namely, North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the RoE), Asia Pacific (Japan, China, India, Thailand, Indonesia and the RoAPAC), Latin America (Brazil, Mexico, and RoLATAM), and the Middle East & Africa
  • To profile the key players in the Market and comprehensively analyze their market shares and core competencies.
  • To track and analyze the competitive developments undertaken in the Market, such as product launches, agreements, expansions, and mergers & acquisitions.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present HLA Typing Market.

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top five companies.

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)

Geographic Analysis

  • Further breakdown of the Rest of Europe Market into Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal among other
  • Further breakdown of the Rest of the Asia Pacific Market into Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries
  • Further breakdown of the Latin American Market into Colombia, Chile, Argentina, and Peru, among other
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 7576
Published ON
May, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the HLA Typing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback